All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

The Global Burden of Disease Expert Group estimated that approximately 30 million people were infected with HIV worldwide in 2013, the majority of whom reside in sub-Saharan Africa \[[@pone.0150970.ref001]\]. Life expectancy and quality of life in those infected with HIV have improved dramatically with the introduction of effective antiretroviral therapy (ART). Between 1990 and 2013, ART saved an estimated 19.1 million life-years in HIV-infected adults \[[@pone.0150970.ref001]\].

With increased longevity in HIV-infected individuals other diseases are likely to develop, similar to the general population. These include obesity, type 2 diabetes mellitus (T2DM) and other cardio-metabolic diseases. Although exposure to risky behaviours of unhealthy diets and reduced physical activity levels contribute to these conditions \[[@pone.0150970.ref002]\], additional influences unique to HIV-infected populations further increase their susceptibility to cardio-metabolic abnormalities. For example, the use of ART is associated with body fat redistribution and cardio-metabolic abnormalities such as hypertension, dyslipidaemia, insulin resistance, and dysglycaemia \[[@pone.0150970.ref003]\]. Moreover, HIV infection itself through chronic inflammation and immune dysfunction mechanisms is assumed to be an important determinant of dyslipidaemia, atherosclerosis and T2DM \[[@pone.0150970.ref004]\].

Cardio-metabolic abnormalities frequently cluster and manifest as the metabolic syndrome (MS), a constellation of interrelated metabolic disorders comprising abdominal obesity, raised blood pressure, dyslipidaemia and hyperglycaemia. The importance of the MS is that it is a powerful predictor of future cardiovascular disease and T2DM \[[@pone.0150970.ref005]\]. Therefore, determining the magnitude of MS in a given population highlights the need for preventive and management strategies, and enables healthcare services planning.

This is particularly relevant in HIV-infected populations who have the potential to develop cardio-metabolic abnormalities and MS through multiple pathways. Notably, the prevalence of MS in HIV-infected populations and the differential contributions, if any, of HIV specific influences on the estimates have yet to be fully examined. Accordingly, we conducted a systematic review and meta-analysis to assess the MS prevalence and its relationship with HIV specific characteristics in the global HIV-infected population.

Methods {#sec006}
=======

Identification of relevant studies {#sec007}
----------------------------------

We undertook a comprehensive electronic search across major databases including Medline, CINAHL, Academic Search Premier, Africa-Wide Information and Scopus to identify relevant studies. The search terms comprised combinations of MESH terms, CINAHL headings, and free words relating to prevalence, metabolic syndrome, and HIV/AIDS ([S1 Table](#pone.0150970.s004){ref-type="supplementary-material"}). Additionally, we traced the citations of identified articles via the ISI Web of Knowledge, and scanned the reference lists of review papers and conference proceedings. We also examined publications on the websites of key organisations such as UNAIDS, WHO, and International AIDS Society. We limited the search to studies reported from January 1998 to April 2015 because highly active antiretroviral therapy (HAART) was introduced only in 1996 \[[@pone.0150970.ref006]\] and the first MS criteria were defined in 1998 \[[@pone.0150970.ref007]\]. The last search data was 30th April 2015.

Selection of included studies {#sec008}
-----------------------------

Two investigators (KAN and NP) independently reviewed the studies by title, abstract and full text where relevant for inclusion. Disagreements were resolved by consensus or by consulting a third investigator (APK). Included studies had to: 1) be population- or hospital-based cross-sectional studies, 2) comprise adults diagnosed with HIV-infection, treated or not; 3) report the prevalence of MS overall and by different subgroups of interest, according to any of the internationally accepted diagnostic criteria for MS ([S3 Table](#pone.0150970.s006){ref-type="supplementary-material"}); or provide enough data to estimate this prevalence; and 4) be published in English or French. We made no restriction by sample size, sampling methods or study setting. For studies reported more than once, the article with the largest number of participants was used. If an article reported multiple surveys conducted in different countries, each survey was counted as a separate study **([Fig 1](#pone.0150970.g001){ref-type="fig"})**.

![Flow diagram for the selection of studies.](pone.0150970.g001){#pone.0150970.g001}

Assessment of the methodological quality of included studies {#sec009}
------------------------------------------------------------

We evaluated the methodological quality of the included studies using a checklist adapted from Hoy et al. \[[@pone.0150970.ref008]\]. It consists of nine questions that assesses the representativeness of the sample, the sampling technique, the response rate, the data collection method, the measurement tools, the case definitions, and the statistical reporting. Each checked question was scored either as "1" or "0" corresponding respectively to "low risk of bias" and "high risk of bias". The total score ranged from 0 to 9 with the overall score categorised as follows: 7 to 9: "low risk of bias", 4 to 6: "moderate risk", and 0 to 3: "high risk" ([S2 Table](#pone.0150970.s005){ref-type="supplementary-material"}). For each included study, we also estimated the precision (C) or margin of error, considering the sample size (SS) and the observed prevalence (p) of MS from the formula SS = Z^2^\*p\*(1-p)/C^2^ where Z was the z-value fixed at 1.96 across studies (corresponding to 95% confidence interval). The desirable margin of error was 5% (0.05) or lower.

Data extraction {#sec010}
---------------

Relevant data for this review were extracted using a purposeful design and a piloted extraction form. The information extracted included 1) Author details \[names and year of publication\]; 2) Study characteristics \[country, study design, setting, data source, sampling method, sample size, data collection period, response rate\]; 3) Participants' characteristics \[age, gender, lifestyle habits (smoking, alcohol misuse), HIV-related factors \[time since diagnosis, severity of the disease, ART regimens and duration of treatment\]; and 4) MS characteristics \[diagnostic criteria used, prevalence, number of participants tested and diagnosed with MS overall and by subgroups of interest\].

Data synthesis and analysis {#sec011}
---------------------------

For each included study, the unadjusted prevalence of MS was estimated (number with MS/total number of participants tested) overall and across major subgroups of interest. We used DerSimonian-Laird random effects models to combine estimates from different studies to generate the overall prevalence of MS according to each diagnostic criteria. The random effects model was chosen over the fixed effects in anticipation of substantial variations in MS prevalence estimates across the included studies. To minimise the effect of extreme prevalence on the overall estimates, we first stabilised the variance of the raw prevalence with a single arcsine transformation before pooling the data \[[@pone.0150970.ref009]\].

To account for the small number of studies that applied some definition criteria, and also to account for similarities between some criteria, a decision was made to group together studies that applied the Adult Treatment Panel III (ATPIII)-2004 and ATPIII-2005 criteria into the ATPIII-2004-2005 group. Furthermore, studies that applied variants of the same criteria (e.g. through the substitution of variables) were assessed together with studies that applied the original criteria.

We assessed the heterogeneity between studies using the Cochran's Q, I^2^ and H statistics \[[@pone.0150970.ref010]\]. Noteworthy is that statistical approaches to assess heterogeneity can yield spurious results within uncontrolled studies \[[@pone.0150970.ref011]\]. We explored the sources of heterogeneity by comparing the prevalence of MS between subgroups defined by naturally occurring categories (e.g. gender and geographic regions), or by using median values of the summary estimates of the continuous characteristics (e.g. age, ART duration) across all eligible studies. Subgroups comparisons then used the Q-test based on the Analysis of the Variance (ANOVA). Publication bias was assessed using the funnel plots supplemented by formal statistical assessments using the Egger test of bias \[[@pone.0150970.ref012]\]. All analyses were performed using the R programme (version 3.0.3 \[2014-03-06\]) and "*meta*" package.

The following sections report the findings of the systematic review and meta-analyses. The data are presented by the overall MS prevalence as well as by subgroups of age, gender, HIV-related factors, study location, publication year, sample size, and smoking status. Within each subgroup, MS prevalence is presented by the definition criteria used.

Results {#sec012}
=======

The review process {#sec013}
------------------

The process for selecting the relevant studies is summarised in [Fig 1](#pone.0150970.g001){ref-type="fig"}. In total, 1280 records were identified via database searches. After removing all duplicates, we scanned the titles and abstracts of 888 articles, of which 78 articles were further reviewed via full-texts. Of these, 59 articles met the inclusion criteria and were selected for this review. One article reported surveys conducted in seven South American countries, leading to a total of 65 studies in the main analyses.

Methodological quality of included studies {#sec014}
------------------------------------------

In all, 18 studies were categorised as having a low risk of bias while the remainder had a moderate risk of bias. However, 37 studies did not indicate how participants were selected; seven studies reported some form of random selection whereas 21 studies indicated a non-random sampling technique. A total of 25 studies reported the response rates which ranged from 31.2% to 100% (median 88%).

Characteristics of included studies {#sec015}
-----------------------------------

The characteristics of the included studies are summarised in [Table 1](#pone.0150970.t001){ref-type="table"}. Studies from all continents were represented as follows: Europe: 23, the Americas: 26, Africa: nine and Asia: four, while three studies were intercontinental. Of the 65 included studies, 33 were localised studies, mainly conducted in urban settings, while the rest had national coverage. With regards to the actual study sites, the majority (58) were solely hospital- or clinic-based, four were community-based and three studies involved both locales. While about half of the studies (34) collected data before or during 2007, only one-fifth (12 studies) were published in the same period.

10.1371/journal.pone.0150970.t001

###### Characteristics of the studies included in the review.

![](pone.0150970.t001){#pone.0150970.t001g}

  Reference                                                   Publication year   Country                                                          Area                Study site                    Study type   Study period   Sampling      Sample size   Response rate (%)   Mean age (years)   Selection criteria                                                                                Quality grade [\*](#t001fn002){ref-type="table-fn"} (Risk)   Precision (margin of error)
  ----------------------------------------------------------- ------------------ ---------------------------------------------------------------- ------------------- ----------------------------- ------------ -------------- ------------- ------------- ------------------- ------------------ ------------------------------------------------------------------------------------------------- ------------------------------------------------------------ -----------------------------
  **Intercontinental**                                                                                                                                                                                                                                                                                                                                                                                                                                            
  Samaras, et al \[[@pone.0150970.ref025]\]                   2007               USA, Europe, Australia, Asia, South America                      National            Hospital + community          C/C          Not provided   Unspecified   788           NR                  \-                 Age ≥ 17 years; not diagnosed with AIDS                                                           Low                                                          0.03
  Wand, et al \[[@pone.0150970.ref028]\]                      2007               Australia, Brazil, Canada, New Zealand, 17 Europrean countries   Urban               Hospital                      C/S          1999--2002     Random        881           94                  38.7               Adults not receiving ART                                                                          Low                                                          0.02
  Worm, et al \[[@pone.0150970.ref052]\]                      2010               USA, Australia, 21 European countries                            National            Hospital (212 clinics)        C/S          2006--2007     Not random    23852         NR                  38                 Adults on ART and regular follow-up                                                               Low                                                          0.01
  **Americas**                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Baum, et al \[[@pone.0150970.ref016]\]                      2006               USA                                                              National            Community                     C/S          2002--2003     Unspecified   118           NR                  41.7               Adult chronic drug users                                                                          Moderate                                                     0.06
  Jacobson, et al \[[@pone.0150970.ref037]\]                  2006               USA                                                              Urban               Community                     C/S          2000--2003     Unspecified   477           NR                  \-                 Self-selected                                                                                     Moderate                                                     0.04
  Johnsen, et al \[[@pone.0150970.ref027]\]                   2006               USA                                                              National            Hospital                      C/C          2002--2003     Unspecified   97            NR                  41                 Women with BMI≥20 kg/m^2^ and only on ART chronic medications                                     Moderate                                                     0.09
  Mondy, et al \[[@pone.0150970.ref044]\]                     2007               USA                                                              Urban               Hospital                      C/S          2005           Not random    471           78                  \-                 All clinic attendees during the study period                                                      Moderate                                                     0.04
  Adeyemi, et al \[[@pone.0150970.ref060]\]                   2008               USA                                                              Urban               Hospital                      C/S          2005--2006     Unspecified   121           NR                  54                 Age ≥ 50 years; outpatient                                                                        Moderate                                                     0.09
  Sobieszczyk, et al \[[@pone.0150970.ref032]\]               2008               USA                                                              Urban               Hospital + community          C/S          2000--2004     Unspecified   1725          NR                  40                 Women                                                                                             Low                                                          0.02
  Sterling, et al \[[@pone.0150970.ref018]\]                  2008               USA                                                              Urban               Hospital                      C/S          1998--2006     Unspecified   222           82                  45.4               Adults co-infected with HCV                                                                       Moderate                                                     0.04
  Ances, et al \[[@pone.0150970.ref061]\]                     2009               USA                                                              National            Hospital                      C/C          Not provided   Unspecified   66            NR                  41                 Cryptogenic stroke (case subgroup)                                                                Moderate                                                     0.09
  Pullinger, et al \[[@pone.0150970.ref024]\]                 2010               USA                                                              Urban               Community                     C/S          2005--2007     Unspecified   296           84.6                45.3               Age ≥ 18 years; diagnosed duration ≥3 months                                                      Moderate                                                     0.05
  Krishnan, et al \[[@pone.0150970.ref038]\]                  2012               USA                                                              National            Hospital                      C/S          2001--2007     random        2247          88                  \-                 Age ≥13 years                                                                                     Low                                                          0.02
  Hadigan, et al \[[@pone.0150970.ref062]\]                   2013               USA                                                              Urban               Hospital (2 clinics)          C/S          2007--2011     Not random    182           72                  45                 Absence of chronic NCDs or co-infection                                                           Moderate                                                     0.05
  Tiozzo, et al \[[@pone.0150970.ref063]\]                    2015               USA                                                              Urban               Hospital                      C/S          2013           Not random    89            90                  48                 Age ≥18 years on ART                                                                              Moderate                                                     0.1
  Da Silva, et al \[[@pone.0150970.ref064]\]                  2009               Brazil                                                           Urban               Hospital (7 centres)          C/S          2004--2006     Not random    319           NR                  39.5               ART use ≥ 2 months, and no anti- lipid agents                                                     Moderate                                                     0.04
  Cahn, et al \[[@pone.0150970.ref023]\]                      2010               7 Latin American countries                                       National            Hospital (61 centres)         C/S          2006--2007     Unspecified   4010          NR                  41.9               ART use ≥1 month                                                                                  Moderate                                                     0.01
  Leite, et al \[[@pone.0150970.ref030]\]                     2010               Brazil                                                           Urban               Hospital                      C/S          2008           Unspecified   100           NR                  \-                 \-                                                                                                Moderate                                                     0.1
  Ramirez-Marrero, et al \[[@pone.0150970.ref020]\]           2010               Puerto Rico                                                      Urban               Hospital + community          C/S          2003--2007     Random        897           31.2                44.7               \-                                                                                                Low                                                          0.03
  Lauda, et al \[[@pone.0150970.ref065]\]                     2011               Brazil                                                           Urban               Hospital                      C/S          2007--2008     Unspecified   249           NR                  \-                 Age ≥18 years                                                                                     Moderate                                                     0.05
  Alencastro, et al \[[@pone.0150970.ref066]\]                2012               Brazil                                                           Urban               Hospital                      C/S          Not provided   Not random    1240          96                  38.6               Age 18--79 years                                                                                  Low                                                          0.02
  Gasparotto, et al \[[@pone.0150970.ref067]\]                2012               Brazil                                                           National            Hospital (multiple-centres)   C/S          Not provided   Unspecified   614           NR                  42.6               Age ≥18 years; ART use ≥1 year; viral load ≤50 copies/ml                                          Moderate                                                     0.04
  Signorini, et al \[[@pone.0150970.ref043]\]                 2012               Brazil                                                           National            Hospital                      C/S          2005           Unspecified   819           NR                  41                 Age ≥18 years                                                                                     Low                                                          0.03
  **Europe**                                                                                                                                                                                                                                                NR                                                                                                                                                                                                    
  Gazzaruso, et al \[[@pone.0150970.ref068]\]                 2003               Italy                                                            National            Hospital                      C/S          Not provided   Unspecified   287           NR                  41                 ART use                                                                                           Moderate                                                     0.05
  Jerico, et al \[[@pone.0150970.ref019]\]                    2005               Spain                                                            Urban               Hospital                      C/S          2003           Unspecified   710           88                  41.9               Age ≥20 years; no evidence of AIDS or ART disruption                                              Low                                                          0.03
  Bergersen, et al \[[@pone.0150970.ref069]\]                 2006               Norway                                                           Urban               Hospital                      C/S          2000--2001     Not random    263           78                  43.3               \-                                                                                                Moderate                                                     0.04
  Estrada, et al \[[@pone.0150970.ref070]\]                   2006               Spain                                                            National            Hospital                      C/S          Not provided   Not random    146           NR                  40.6               ART use ≥6 months, no active opportunistic affection                                              Moderate                                                     0.06
  Bonfanti, et al \[[@pone.0150970.ref071]\]                  2007               Italy                                                            Urban               Hospital (18 centers)         C/S          2005           Not random    1243          98.4                43.2               \-                                                                                                Moderate                                                     0.02
  Palacios, et al \[[@pone.0150970.ref051]\]                  2007               Spain                                                            National            Hospital                      C/S          2002--2003     Unspecified   60            81                  40.9               ART use ≥48 weeks                                                                                 Moderate                                                     0.09
  Badiou, et al \[[@pone.0150970.ref049]\]                    2008               France                                                           National            Hospital                      C/S          1999           Not random    232           NR                  41                 \-                                                                                                Low                                                          0.04
  Martin, et al (SHIVA study) \[[@pone.0150970.ref026]\]      2008               France                                                           Urban               Hospital                      C/S          2003           Unspecified   140           86.9                \-                 \-                                                                                                Moderate                                                     0.04
  Schillaci, et al \[[@pone.0150970.ref072]\]                 2008               Italy                                                            Urban               Hospital                      C/C          Not provided   Unspecified   39            NR                  37                 Outpatients; no ART                                                                               Moderate                                                     0.12
  Hansen, et al \[[@pone.0150970.ref073]\]                    2009               Denmark                                                          National            Hospital                      C/S          2004--2006     Unspecified   566           75.7                44.1               Age ≥18 years                                                                                     Low                                                          0.04
  Young, et al \[[@pone.0150970.ref074]\]                     2009               Switzerland                                                      National            Hospital                      C/S          2000--2006     Unspecified   1644          70                  \-                 ART use                                                                                           Low                                                          0.02
  Bonfanti, et al \[[@pone.0150970.ref050]\]                  2010               Italy                                                            Urban               Hospital (14 centers)         C/S          2007           Not random    292           NR                  37                 Age ≥18 years; ART naive                                                                          Moderate                                                     0.04
  Calza, et al \[[@pone.0150970.ref075]\]                     2011               Italy                                                            Urban               Hospital                      C/S          2009           Not random    755           NR                  37                 Outpatients                                                                                       Moderate                                                     0.02
  Cubero, et al \[[@pone.0150970.ref042]\]                    2011               Spain                                                            National            Hospital                      C/S          Not provided   Not random    159           NR                  39                 1^st^ line ART regimen, no kidney or liver disease, no lipid modifying treatment or hormone use   Moderate                                                     0.07
  Elgalib, et al \[[@pone.0150970.ref041]\]                   2011               UK                                                               Urban; Peri-urban   Hospital (2 centers)          C/S          2005--2006     Random        678           66.4                39.5               \-                                                                                                Low                                                          0.03
  Freitas, et al \[[@pone.0150970.ref029]\]                   2011               Portugal                                                         National            Hospital                      C/S          Not provided   Unspecified   345           NR                  43.8               ART use lipodystrophy                                                                             Moderate                                                     0.05
  Guaraldi, et al \[[@pone.0150970.ref076]\]                  2011               Italy                                                            National            Hospital (2 centers)          C/S          2007--2008     Unspecified   103           NR                  46.9               Age ≥18 years on ART                                                                              Moderate                                                     0.06
  Janiszewski et al \[[@pone.0150970.ref077]\]                2011               Italy                                                            National            Hospital                      C/S          2005--2009     Unspecified   2322          NR                  \-                 ART use ≥ 18 months                                                                               Moderate                                                     0.02
  Biron, et al \[[@pone.0150970.ref047]\]                     2012               France                                                           National            Hospital (5 centers)          C/S          2000--2007     Not random    269           85.7                43                 Aged ≥18 years, ART use for 1--4 years without disruption                                         Low                                                          0.05
  Guaraldi, et al \[[@pone.0150970.ref031]\]                  2012               Italy                                                            National            Hospital (2 centers)          C/S          2009--2010     Unspecified   133           NR                  \-                 Men, sexually active in the 4 last weeks                                                          Moderate                                                     0.07
  Maloberti, et al \[[@pone.0150970.ref054]\]                 2013               Italy                                                            National            Hospital                      C/S          Not provided   Unspecified   108           NR                  \-                 Free of known CVD risk factors                                                                    Moderate                                                     0.07
  De Socio, et al (HIV-Hy study) \[[@pone.0150970.ref021]\]   2014               Italy                                                            National            Hospital                      C/S          2010--2011     Not random    765           93                  45.6               \-                                                                                                Moderate                                                     0.03
  Sawadogo, et al \[[@pone.0150970.ref022]\]                  2014               Burkina Faso                                                     Urban               Hospital                      C/S          2011           Random        400           NR                  41.4               Age ≥18 years; ART use ≥ 6 months                                                                 Moderate                                                     0.03
  **Africa**                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Zannou, et al \[[@pone.0150970.ref017]\]                    2009               Benin                                                            Urban               Hospital                      C/S          2004--2005     Unspecified   79            90                  38                 Age ≥ 16 years; ART use; not obese                                                                Moderate                                                     0.07
  Awotedu, et al \[[@pone.0150970.ref013]\]                   2010               South Africa                                                     Urban               Hospital                      C/S          2009--2010     Not random    196           NR                  36.8               No lipid modifying medications                                                                    Moderate                                                     0.07
  Fourie, et al \[[@pone.0150970.ref078]\]                    2010               South Africa                                                     Urban; Rural        Community                     C/S          2005           Random        300           NR                  44                 Aged ≥35 years; no chronic medications or self-reported disease                                   Moderate                                                     0.05
  Ayodele, et al \[[@pone.0150970.ref048]\]                   2012               Nigeria                                                          Urban               Hospital                      C/S          Not provided   Not random    291           94                  39.5               No liver or thyroid disease or concurrent infections                                              Moderate                                                     0.05
  Berhane, et al \[[@pone.0150970.ref079]\]                   2012               Ethiopia                                                         Urban               Hospital                      C/S          2010           Not random    313           100                 \-                 Age ≥18 years, ART use ≥6 weeks                                                                   Moderate                                                     0.05
  Muhammad, et al \[[@pone.0150970.ref080]\]                  2013               Nigeria                                                          Urban               Hospital                      C/S          2009           Not random    200           NR                  32.5               Age ≥18 years; not diagnosed with hypertension, diabetes or dyslipidaemia before commencing ART   Moderate                                                     0.05
  Ngatchou, et al \[[@pone.0150970.ref015]\]                  2013               Cameroon                                                         Urban               Hospital                      C/S          2009--2010     Not random    108           NR                  39                 ART-naïve adults; no documented diabetes, hypertension or dyslipidaemia                           Moderate                                                     0.09
  Mbunkah, et al \[[@pone.0150970.ref046]\]                   2014               Cameroon                                                         National            Hospital                      C/S          2010--2011     Unspecified   173           100                 38.7               \-                                                                                                Low                                                          0.05
  Tesfaye, et al \[[@pone.0150970.ref045]\]                   2014               Ethiopia                                                         Urban               Hospital                      C/S          2013           Random        374           97.2                32.6               Age ≥18 years                                                                                     Low                                                          0.04
  **Asia**                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Gupta, et al \[[@pone.0150970.ref040]\]                     2011               India                                                            Urban               Hospital                      C/S          2007--2009     Not random    68            NR                  35.9               ART-naïve; no chronic medications                                                                 Moderate                                                     0.1
  Wu, et al \[[@pone.0150970.ref014]\]                        2012               Taiwan                                                           National            Hospital                      C/S          2008--2009     Unspecified   803           60.2                \-                 Age ≥18 years                                                                                     Low                                                          0.03
  Bajaj, et al \[[@pone.0150970.ref081]\]                     2013               India                                                            Urban               Hospital                      C/S          2010--2011     Not random    70            NR                  \-                 No comorbid diabetes or hypertension                                                              Moderate                                                     0.09
  Jantarapakde, et al \[[@pone.0150970.ref082]\]              2014               Thailand                                                         National            Hospital (6 centres)          C/S          2009--2011     Unspecified   580           99                  37                 Adults                                                                                            Low                                                          0.03

BMI, body mass index; C/C, case-control; C/S, cross-sectional; HCV, hepatitis C virus; NCDs, non-communicable diseases; NR, not reported.

\*Quality grades: Low risk (score range, 7--9), Moderate risk (score range, 4--6), and High risk (score range, 0--3).

The studies consisted of 39 to 23853 participants with men comprising 19--95% (median 70.7%) of the samples \[[@pone.0150970.ref013],[@pone.0150970.ref014]\]. The median age of participants was 41 years (range 17--73 years). Smoking prevalence, reported in 47 studies, was 0--84% (median 39.8%) \[[@pone.0150970.ref015],[@pone.0150970.ref016]\]. In the 37 studies with data on CD4 cell count, levels ranged from 105 cells/μL (Benin) \[[@pone.0150970.ref017]\] to 535 cells/μL (USA) \[[@pone.0150970.ref018]\] (median 394 cells/μL). The timespan of diagnosed HIV infection, reported in 20 studies, was 19.3 to 224.4 months \[[@pone.0150970.ref015],[@pone.0150970.ref018]\] (median 67.6 months) while the duration of ART, described in 21 studies, was 14.6--78 months \[[@pone.0150970.ref017],[@pone.0150970.ref019]\], (median 27 months). In the 28 studies that reported on ART usage, 45--94% of the HIV-infected participants, were on ART \[[@pone.0150970.ref020],[@pone.0150970.ref021]\] (median 76.2%). Of those on ART, 17.3--61.5% (median 37.4%) were on protease inhibitors (PIs) \[[@pone.0150970.ref022],[@pone.0150970.ref023]\], 19.4% (median 43.4%) on non-nucleoside reverse transcriptase inhibitors (NNRTIs) \[[@pone.0150970.ref022],[@pone.0150970.ref024]\], and 1.5--85.5% (median 77.0%) on nucleoside reverse transcriptase inhibitors (NRTIs) \[[@pone.0150970.ref021],[@pone.0150970.ref025]\]. Very few studies provided information on the stage of the disease ([S4 Table](#pone.0150970.s007){ref-type="supplementary-material"}).

The included studies applied various international criteria to diagnose MS ([S5 Table](#pone.0150970.s008){ref-type="supplementary-material"}). Fifty-one studies applied a single set of criteria; the most frequently used was the ATPIII-2001 in 30 studies followed by the ATPIII-2004-2005 (14 studies). The International Diabetes Federation (IDF)-2005, Joint Interim Statement (JIS)-2009 and modified ATPIII-2005 criteria were used in 2 studies each while the European Group for the Study of Insulin Resistance (EGIR)-2003 in one only. Of the 14 studies that compared the MS prevalence using two or more criteria, the following combinations were reported: two criteria: IDF-2005 + ATPIII-2001 (7 studies), and IDF-2005 + ATPIII-2005 (4 studies), and three criteria (1 study each): IDF-2005 + ATPIII-2005 + JIS-2009; IDF-2005 + ATPIII-2001 + EGIR-2003; IDF-2005 + ATPIII-2001 + EGIR-2003.

Overall prevalence of metabolic syndrome {#sec016}
----------------------------------------

The most commonly used criteria to determine MS prevalence, alone or in combination with other criteria, were the ATPIII-2001 ([Fig 2](#pone.0150970.g002){ref-type="fig"}: 38 studies, n = 16984), IDF-2005 ([Fig 3A](#pone.0150970.g003){ref-type="fig"}: 16 studies, n = 8250) and ATPIII-2004-2005 definitions ([Fig 3B](#pone.0150970.g003){ref-type="fig"}: 20 studies, n = 11255). The overall MS prevalence rates by these criteria were 16.7% (95%CI, 14.6--18.8; I^2^ = 92.1%, p-*heterogeneity*\<0.001), 18.0% (95%CI: 14.0--22.4; I^2^ = 95.8%, p\<0.001) and 24.6% (95%CI: 20.6--28.8; I^2^ = 95.8%, p\<0.001), respectively. The prevalence ranges were 7.2% \[[@pone.0150970.ref026]\] to 31% \[[@pone.0150970.ref027]\] (ATPIII 2001), 7.8% \[[@pone.0150970.ref028]\] to 43.2% \[[@pone.0150970.ref029]\] (IDF 2005) and 12.3% \[[@pone.0150970.ref022]\] to 52% \[[@pone.0150970.ref030]\] (ATPIII 2004--2005).

![Overall metabolic syndrome prevalence in the HIV-infected: Adult Treatment Panel III (ATPIII) 2001 criteria.\
For each study the black box represents the study estimate (prevalence of metabolic syndrome \[MS\]) and the horizontal bar about the 95% confidence intervals (95%CI). The size of the boxes is proportional to the inverse variance. The diamond at the lower tail of the figure is for the pooled effect estimates from random effects models. The proportional contribution of each study (weight) to the pooled estimates is also shown, together with the prevalence estimates and measures of heterogeneity. The dotted vertical line is centred on the pooled estimates.](pone.0150970.g002){#pone.0150970.g002}

![Overall metabolic syndrome prevalence in the HIV-infected.\
Figure panels are for the prevalence of metabolic syndrome according to the International Diabetes Federation 2005 criteria (panel a), and according to the Adult Treatment Panel III 2005 criteria overall and by continent (panel b). For each study the black box represents the study estimate (prevalence of metabolic syndrome \[MS\]) and the horizontal bar about the 95% confidence intervals (95%CI). The size of the boxes is proportional to the inverse variance. The diamond at the lower tail of the figure is for the pooled effect estimates from random effects models. The proportional contribution of each study (weight) to the pooled estimates is also shown, together with the prevalence estimates and measures of heterogeneity. The dotted vertical line is centred on the pooled estimates.](pone.0150970.g003){#pone.0150970.g003}

The highest overall MS prevalence was by the EGIR criteria (31.3%, 95%CI: 26.8--36.0; I^2^ = 9.8%, p = 0.300) used in two studies (n = 446) ([S1 Fig](#pone.0150970.s001){ref-type="supplementary-material"}). A similarly high prevalence by the JIS criteria (29.6%, 95%CI: 22.9--36.8; I^2^ = 91%, p\<0.001) was based on four studies (n = 2404) ([S2 Fig](#pone.0150970.s002){ref-type="supplementary-material"}). MS prevalence by the modified ATPIII 2005 criteria, obtained from two studies (n = 23919), was also high at 27.9% (95%CI: 6.7--56.5; I^2^ = 95.8%, p\<0.001) ([S3 Fig](#pone.0150970.s003){ref-type="supplementary-material"}). However, there were relatively few studies that determined the MS by these three criteria. The margin of error (precision) across studies ranged from 1% to 12%, with only 18 studies (28%) having a margin of error \>5% ([Table 1](#pone.0150970.t001){ref-type="table"}).

With a wide range of 16.7% to 31.3%, the pooled prevalence of MS differed significantly by the various diagnostic criteria (p\<0.001). Unsurprisingly, however, MS prevalence by modified criteria was similar to that of studies that used the related original definition ([S5 Table](#pone.0150970.s008){ref-type="supplementary-material"}). There was insufficient evidence of publication bias (all p ≥0.060 for the Egger test) except for studies that used the ATPIII 2001 criteria (p-Egger test = 0.040; [Fig 4](#pone.0150970.g004){ref-type="fig"})

![Funnel plots for included studies across different diagnostic criteria for metabolic syndrome.\
For each diagnostic criteria, the arcsine transformed proportion of participants with metabolic syndrome (relative to the total sample) for each relevant study (horizontal axis) is plotted against its standard error (vertical axis), and represented by the dots. When the dots distribute symmetrically in a funnel shape, this implies an absence of bias. A p-value \<0.05 (Egger test) indicates significant publication bias.](pone.0150970.g004){#pone.0150970.g004}

Prevalence of metabolic syndrome within and across subgroups {#sec017}
------------------------------------------------------------

Some of the findings are presented in the accompanying tables and figures while other data such as the prevalence of MS by age, intra-country location, duration of HIV infection, ART status, treatment period and year of publication are reported in the supplementary tables and figures.

### Age {#sec018}

Older (\>median age 41 years) compared with younger participants (≤41years) had higher MS prevalence ([S6 Table](#pone.0150970.s009){ref-type="supplementary-material"}): ATPIII-2001: 19.7% vs. 13.2%, p\<0.001, ATIII 2004--2005: 26.6% vs. 21.5%, p = 0.479 and IDF-2005: 22.3% vs. 16.4%, p = 0.361. Substantial heterogeneity was apparent within age-groups regardless of the criteria (all p-*heterogeneity*\<0.001).

### Gender {#sec019}

Thirty-two of the 65 studies presented the MS data by gender; of these a single study was conducted in men only (Italy) \[[@pone.0150970.ref031]\] and two in women only (USA) \[[@pone.0150970.ref027],[@pone.0150970.ref032]\]. The criteria most commonly used was the ATPIII 2001 in 16 studies for men (n = 8269) and 17 studies for women (n = 3971). This was followed by the ATPIII 2004--2005 (13 studies, men: n = 5742, women: n = 4470) and IDF 2005 definitions (11 studies, men: n = 3556, women: n = 2293). The MS prevalence in men and women was as follows: ATPIII 2001: 14.6% (95%CI: 11.5--18.1) and 17.5% (95%CI: 14.0--21.2); ATPIII 2004--2005: 23.7% (95%CI: 19.0--28.7) and 26.7% (95%CI: 20.8--33.0); and IDF 2005: 13.4% (95%CI: 8.7--18.9) and 23.2% (95%CI: 15.9--31.4); [Fig 5](#pone.0150970.g005){ref-type="fig"} and [S6 Table](#pone.0150970.s009){ref-type="supplementary-material"}. MS prevalence by the various criteria was significantly different in men (p = 0.001) but not in women (p = 0.118). Heterogeneity presented within gender-groups across criteria (all p-*heterogeneity*\<0.001).

![Pooled metabolic syndrome prevalence in the HIV-infected presented by gender: International Diabetes Federation 2005 criteria.\
For each study the black box represents the study estimate (prevalence of metabolic syndrome \[MS\]) and the horizontal bar about the 95% confidence intervals (95%CI). The size of the boxes is proportional to the inverse variance. The diamond at the lower tail of the figure is for the pooled effect estimates from random effects models. The proportional contribution of each study (weight) to the pooled estimates is also shown, together with the prevalence estimates and measures of heterogeneity. The dotted vertical line is centred on the pooled estimates. Furthermore, pooled effect estimates are provided separately by gender. The horizontal arrow head indicates that the representation of the effect estimates and 95% confidence intervals has been truncated.](pone.0150970.g005){#pone.0150970.g005}

HIV-related factors {#sec020}
-------------------

*Duration of diagnosed HIV infection*: The prevalence of MS, categorised by the duration of diagnosed HIV infection (median cut-off point 68 months), differed across MS criteria ([S6 Table](#pone.0150970.s009){ref-type="supplementary-material"}). By the ATPIII-2001 definition, MS prevalence was significantly higher (p = 0.044) in participants with longer (20.6%, 95%CI: 13.8--28.4) compared to shorter duration of diagnosed HIV-infection (13.2%, 95%CI: 11.2--15.4). However, by the ATPIII-2004-2005, MS prevalence was not significantly different: longer: 32.0% vs. shorter: 19.1%, p = 0.251. There was substantial heterogeneity across and within criteria for MS prevalence by the duration of diagnosed HIV infection; all p-*heterogeneity*\<0.030 for within criteria except for studies below the median duration which used the ATPIII-2001 criteria (p-*heterogeneity* = 0.581)

*CD4 counts*: Using a median cut-off point of 394 cells/μL, MS prevalence in participants with high CD4 counts was significantly lower than in those with low CD4 counts by the IDF 2005 criteria: 10.4% (8.2--12.9) vs. 17.5% (14.4--20.8), p\<0.001 ([S6 Table](#pone.0150970.s009){ref-type="supplementary-material"}). However, there was little difference in MS prevalence by CD4 count levels using the ATPIII-2001 (17.4% vs. 15.6%, p = 0.514) and ATPIII-2004-2005 definitions (24.6% vs. 26.5%, p = 0.747). The prevalence across MS diagnostic criteria was significantly different by CD4 count levels (all p≤0.020). Substantial heterogeneity was noted in MS prevalence by CD4 count levels within studies that applied the ATPIII-2001 and ATPIII-2004-2005 criteria (all p-*heterogeneity*≤0.035) but not within studies that used the IDF-2005 definition (p-*heterogeneity*≥0.272).

*Exposure to antiretroviral therapy*: In studies that included treatment status **(**[S6 Table](#pone.0150970.s009){ref-type="supplementary-material"}**)**, the most commonly used MS criteria was the ATPIII 2001 (ART-exposed: 20 studies, n = 12148, ART-naïve: 17 studies, n = 2659). MS prevalence, at 18.4% (95% CI: 15.9--21.1) in the ART-exposed, was significantly higher (p = 0.001) than in the ART-naïve (11.8%, 95%CI: 9.3--14.7) ([Fig 6](#pone.0150970.g006){ref-type="fig"}). MS prevalence by the IDF 2005 criteria was also higher in the ART-exposed (19.6%, 95%CI: 14.2--25.6) compared to the ART-naïve (14.9%, 95%CI: 8.6--22.6) but this difference was not significant; prevalence was similar by the ATPIII 2004--2005 definition (21.6%, 95%CI: 13.5--31.0 vs. 19.9%, 95%CI: 18.3--21.5). Interestingly, MS prevalence by the various criteria was similar in the ART-exposed (p = 0.730) but significantly different in the ART-naïve (p\<0.001). Excluding the non-ART studies based on the ATPIII-2004-2005 where homogeneity was found (p-*heterogeneity* = 0.398), there was significant heterogeneity within ART-exposed and ART-naïve groups (all p-*heterogeneity*\<0.001).

![Pooled metabolic syndrome prevalence in the HIV-infected presented by antiretroviral therapy (ART) use: Adult Treatment Panel 2001 criteria.\
For each study the black box represents the study estimate (prevalence of metabolic syndrome \[MS\]) and the horizontal bar about the 95% confidence intervals (95%CI). The size of the boxes is proportional to the inverse variance. The diamond at the lower tail of the figure is for the pooled effect estimates from random effects models. The proportional contribution of each study (weight) to the pooled estimates is also shown, together with the prevalence estimates and measures of heterogeneity. The dotted vertical line is centred on the pooled estimates. Furthermore, pooled effect estimates are provided separately by ART use. The horizontal arrow head indicates that the representation of the effect estimates and 95% confidence intervals has been truncated.](pone.0150970.g006){#pone.0150970.g006}

*Proportions of ART users and duration of ART treatment*: MS prevalence by a high or low proportion of ART users (median cut-off point 76.2%) was not significantly different within criteria: ATPIII 2001: 15.8% vs. 19.1%, p = 0.172; ATPIII 2004--2005: 38.3% vs. 23.8%, p = 0.256; IDF 2005: 14.4% vs. 19.4%, p = 0.176. Using a cut-off point of 27 months for the median length of ART use, MS prevalence was not significantly different for a longer or shorter treatment duration within MS criteria: ATPIII 2001: 17.1% vs. 15.6%, p = 0.649; ATPIII 2004--2005: 25.6% vs. 14.2%, p = 0.192; IDF 2005: 14.6% vs. 13.4%, p = 0.811. The prevalence within the two sub-groups was similar across MS criteria (all p≥0.111). Substantial heterogeneity was noted within all the above subgroups (all p-*heterogeneity*\<0.001).

*ART regimen*: The median proportion of participants using PIs across the included studies was 37.4% ([S6 Table](#pone.0150970.s009){ref-type="supplementary-material"}). Using this cut-off point, the pooled MS prevalence in studies with more compared to fewer PI users by the IDF 2005 criteria was 18.5% (95%CI: 12.3--25.6) from six studies (n = 4927) versus 10.0% (95%CI: 7.2--13.4) (p = 0.016) in a single study (n = 400). However, the MS prevalence by proportion of PI users was not significantly different by the ATPIII 2001 (17.7% vs. 19.3%, p = 0.593) and ATPIII 2004--2005 definitions (25.8% vs. 30.4%, p = 0.517). MS prevalence, determined by the various criteria, differed across studies of PI users (p = 0.022) and in those with fewer median participants on PIs (p = 0.001).

The median proportion of participants using NNRTIs was 43.4%, the cut-off value used to determine a high and low proportion of users. The pooled MS prevalence in studies with more compared to fewer NNRTI users was 17.2% (95%CI: 9.5--26.6) versus 33.8% (95%CI: 23.4--45.1) (p = 0.020) by the ATPIII 2004--2005 criteria. MS prevalence according to NNRTI regimen status was not significantly different by the ATPIII 2001 (19.5% vs. 15.1%, p = 0.221) and IDF 2005 criteria (10.5% vs. 19.8%, p = 0.058). However, MS prevalence within the two NNRTI subcategories was significantly different by the various MS criteria (all p≤0.007), ([S6 Table](#pone.0150970.s009){ref-type="supplementary-material"}).

In studies with a high proportion of participants on NRTI (median \>77.0%), the pooled prevalence by the ATPIII 2001 criteria was 17.9% (95%CI: 9.4--28.7) compared to 22.8% (95%CI: 14.3--32.7) in studies with fewer participants on NRTIs (p = 0.474) ([S6 Table](#pone.0150970.s009){ref-type="supplementary-material"}). There was insufficient data by the IDF 2005 and ATPIII 2004--2005 criteria for analysis.

Study location {#sec021}
--------------

*Intercontinental*: The ATPIII 2004--2005 MS criteria was the only one commonly used by studies across continents. The pooled MS prevalence by this criteria was the highest in the Americas (9 studies, n = 7450) at 27.3% (95%CI: 21.7--33.4; I^2^ = 96.6%, p\<0.001). This was followed by Europe (5 studies, n = 1571) and Asia (4 studies, n = 1521) where the prevalence was similar. At 24.1% (95%CI: 11.2--40.1; I^2^ = 97.7%, p\<0.001) in Europe and 24.1% (95%CI: 21.6--26.8; I^2^ = 16.8%, p = 0.307) in Asia, MS prevalence on these continents were almost as high as in the Americas. MS prevalence in Africa (2 studies, n = 713), however, was much lower at 16.4% (95%CI: 8.7--25.9; I^2^ = 90%, p = 0.002), ([Fig 3B](#pone.0150970.g003){ref-type="fig"} and [S6 Table](#pone.0150970.s009){ref-type="supplementary-material"}). The differences in prevalence across continents was not statistically significant (p = 0.284).

*Intra-country*: MS prevalence was similar across regional studies compared with the corresponding national data (ATPIII 2001: 16.0% vs. 17.1%, p = 0.607; ATPIII 2004--2005: 24.3% vs. 25.4%, p = 0.861; IDF 2005: 17.4% vs. 18.7%, p = 0.785) ([S6 Table](#pone.0150970.s009){ref-type="supplementary-material"}). According to the criteria used, the prevalence of MS within a country differed in regional studies (p = 0.024) but was not significantly different in national studies (p = 0.109).

Year of publication {#sec022}
-------------------

The prevalence of MS in studies reported before, compared to after, 2010 was significantly higher by the ATPIII 2004--2005 criteria (30.6% vs. 21.5%, p = 0.012) but not by the other definitions (all p≥0.100). However, MS prevalence in the earlier publications differed significantly by criteria (16.4% vs. 30.6% vs. 14.5% for ATPIII-2001, ATPIII-2004-2005, IDF-2005 respectively, p\<0.001).

Sample size and smoking status {#sec023}
------------------------------

The median number of participants per study was 292 with this sample size used to classify studies as either large or small. MS prevalence was similar in large and small studies within criteria: ATPIII 2001:18.3% vs. 15.1%, p = 0.115; ATPIII 2004--2005: 24.7% vs. 25.6%, p = 0.989; IDF 2005: 19.0% vs. 16.1%, p = 0.388. There was no significant difference in prevalence by sample size category across MS criteria (all p≥0.059).

Smoking status {#sec024}
--------------

The absence of a significant difference in the prevalence of MS in studies with a high or low proportion of smokers (median 39.8%) within criteria is demonstrated in [S6 Table](#pone.0150970.s009){ref-type="supplementary-material"}. The prevalence was as follows: ATPIII 2001: 14.8% vs. 17.6%, p = 0.234; ATPIII 2004--2005: 28.8% vs. 22.2%, p = 0.193; IDF 2005: 18.4% vs. 14.6%, p = 0.565. However, MS prevalence varied significantly across criteria in studies with a higher proportion of smokers (p = 0.010). There was substantial heterogeneity within all the above subgroups (all p-*heterogeneity*\<0.001).

Discussion {#sec025}
==========

Overview of MS prevalence {#sec026}
-------------------------

To our knowledge, this is the first comprehensive review and meta-analysis of the MS prevalence in the global HIV-infected population. Among the key findings was the high burden of MS in the HIV-infected population; 16.7--31.3% of HIV-infected adults had MS by the various definitions. The wide prevalence range is indicative of substantial heterogeneities across and within the diagnostic criteria. Two different criteria, the ATPIII-2001 and the EGIR-2003, reported the overall lowest and highest prevalences, respectively. Notably, the differences in prevalences were not fully explained by the major study characteristics. For example, variations in MS prevalence were also apparent within subgroups such as in younger participants, men, the Americas, regional studies, older publications and smokers.

Notably, the MS prevalence in the HIV-infected is within the range of the 17--46% reported in the general population. This highlights that the risk for developing MS in HIV-infected individuals is likely comparable to that in the general population. It also underscores the importance of traditional cardio-metabolic risk factors in the former; these are likely to exert an equal influence on HIV-infected individuals as they do in the general population. The wide range in MS prevalence in the general population mimics that found in this review and is possibly due to similar reasons discussed above \[[@pone.0150970.ref033]--[@pone.0150970.ref035]\].

The similar exposure to cardio-metabolic risk factors in the HIV-infected compared to the general population is likely attributable to the introduction of ART which has dramatically reduced HIV-related morbidity and mortality. ART has prolonged lifespans and subsequently enabled the HIV-infected to be exposed to the same risk factors and diseases as the general population. Reinforcing the likelihood of similar pathways in the development of MS in the HIV-infected and general populations was the higher MS prevalence in older compared to younger HIV-infected individuals, which is mirrored in general populations \[[@pone.0150970.ref033]\].

The higher MS prevalence in women compared to men in this analysis has also been shown in general populations but reports diverge in the latter \[[@pone.0150970.ref033]--[@pone.0150970.ref035]\]. Further research may be required to understand the differences in MS prevalence by gender which is usually driven by higher rates of obesity \[[@pone.0150970.ref036]\]. There may also be HIV specific factors that contribute to greater cardio-metabolic abnormalities in women compared to men that require further investigation.

MS prevalence by diagnostic criteria {#sec027}
------------------------------------

Across the three major criteria (ATPIII 2001, ATPIII 2004--2005, and IDF 2005) used by most studies in this review, the estimated MS prevalence was highest by the ATPIII 2004--2005 definition (24.6%). This was not unexpected because the threshold for hyperglycaemia in the ATPIII 2004--2005 is lower than that for the ATPIII 2001criteria; this leads to more individuals diagnosed with MS by the former classification. Furthermore, the inclusion of lipid-lowering and/or antihypertensive medications in the ATPIII 2004--2005 definition also contributes to a higher MS diagnosis compared with the ATPIII 2001. In contrast, the compulsory incorporation of waist circumference in the IDF 2005 criteria excludes many HIV-infected participants with abnormal biochemical parameters but normal waist circumference from the diagnosis. This is of particular relevance and frequently reported in HIV studies \[[@pone.0150970.ref025],[@pone.0150970.ref037]--[@pone.0150970.ref041]\].

Not surprisingly, few studies that used more than one definition to diagnose MS applied the same combination of criteria \[[@pone.0150970.ref025],[@pone.0150970.ref042]\]. In this review, direct comparison of MS prevalence by the various criteria is not meaningful because there was substantial overlap of the confidence intervals around the prevalence estimates. Also, only few studies used multiple diagnostic criteria which would limit the value of such an analysis.

HIV-related influences on MS prevalence {#sec028}
---------------------------------------

Although HIV specific characteristics were associated with the prevalence of MS in the current analyses, these need to be interpreted with care because of the inability to control for the many confounding influences. Nonetheless, the association of MS prevalence with a greater duration of diagnosed HIV infection accords with the influence of HIV infection on the development of cardio-metabolic abnormalities. Then again, a longer interval since HIV diagnosis likely correlates with older age, which is a risk factor for MS in both the HIV-infected and general populations. It may also possibly reflect the specific effects of prolonged ART.

The relation between CD4 count and MS was unclear with some studies reporting a direct link \[[@pone.0150970.ref043],[@pone.0150970.ref044]\] while others demonstrate the inverse \[[@pone.0150970.ref045]\] or no association \[[@pone.0150970.ref046],[@pone.0150970.ref047]\]. However, these findings were based on only seven studies and did not report the viral loads \[[@pone.0150970.ref013],[@pone.0150970.ref017],[@pone.0150970.ref022],[@pone.0150970.ref040],[@pone.0150970.ref042],[@pone.0150970.ref048],[@pone.0150970.ref049]\]. Without such information it is difficult to draw conclusions on this relationship. A high viral load has been associated with the development of MS, possibly contributing to the high incidence of low high density lipoprotein cholesterol (HDL-C) levels and high triglycerides in some studies \[[@pone.0150970.ref016],[@pone.0150970.ref050]\].

The higher MS prevalence in ART-exposed compared to ART-naïve participants by the ATPIII-2001 criteria was consistent with findings from prospective studies. One of these studies demonstrated an increase in MS prevalence from 16.6% to 25% with an incidence of 14/100 patients-year among participants initiated and maintained on the same HAART regimen for 48 weeks \[[@pone.0150970.ref051]\]. In another study, a large international, multicentre, randomised trial conducted for three years after the initiation of ART, the incidence of MS was 12/100 patients-year and 8/100 patients-year according to the ATPIII 2001 and the IDF 2005 criteria, respectively \[[@pone.0150970.ref028]\]. Also, the D:A:D study which followed HIV patients on ART over a long period, demonstrated a substantial increase in MS prevalence \[[@pone.0150970.ref052]\].

ART regimen was significantly associated with MS with notable differential findings by the class of drug used. The higher MS prevalence in studies with a greater compared to smaller proportion of PI users accords with four trials where PI-based regimens were found to accelerate progression to MS \[[@pone.0150970.ref037],[@pone.0150970.ref038]\]. The initiation of ART leads to chronic inflammation and an incompletely restored immune system. This may perhaps be the link between PI use and the development of MS \[[@pone.0150970.ref053],[@pone.0150970.ref054]\]. Furthermore, PI drugs have been reported to be associated with more severe dyslipidaemia compared to NNRTI, which is a feature of metabolic syndrome. This would explain at least in part the higher prevalence of MS in patients on PI. Patients on this regimen thus need to be closely monitored for the development of cardio-metabolic abnormalities. Moreover, once such abnormalities arise, it is important to review ART management and change to metabolically neutral regimens.

An alternative ART regimen to PIs in patients with MS may be NNRTIs because a lower MS prevalence, by some criteria, was detected in studies with a high compared to low proportion of participants on these drugs. Although our analyses were based on only seven studies \[[@pone.0150970.ref014],[@pone.0150970.ref020],[@pone.0150970.ref022],[@pone.0150970.ref029],[@pone.0150970.ref037],[@pone.0150970.ref041],[@pone.0150970.ref044]\] this suggests that, unlike PIs, NNRTIs do not adversely influence cardio-metabolic function and may possibly even have a beneficial impact. Indeed, a randomised controlled study reported improvements in cardio-metabolic profiles with increases in HDL-C levels in patients on nevirapine and nelfinavir \[[@pone.0150970.ref055]\]. On the other hand, several prospective trials have found no association between the use of NNRTIs and MS \[[@pone.0150970.ref037],[@pone.0150970.ref038]\]. Further research is required to clearly describe the relationship between NNRTIs and cardio-metabolic functioning, particularly since there is a dearth of data on the influence of this class of ART on MS.

Other influences on MS prevalence {#sec029}
---------------------------------

Although there was no difference in MS prevalence between studies with a high and low proportion of smokers, conclusions on the absence of an association should be cautioned against. The studies analysed included only current smokers with no consideration given to recent smoking cessation or ex-smokers. Reports describe the duration of smoking cessation to be inversely related to future cardiovascular disease risk to a moderate degree. Furthermore, aspects not considered in this review such as the smoking interval and the quantity smoked have been strongly correlated with the development of MS and atherosclerosis progression \[[@pone.0150970.ref056]--[@pone.0150970.ref058]\].

The lower MS prevalence by the ATPIII 2004--2005 criteria in recent compared to older publications was surprising. We expected the trend to mimic that of the general population with a rise in MS prevalence in the HIV-infected over time. Moreover, with the introduction and widespread uptake of ART leading to longevity, we anticipated the subsequent development of MS with age, which would be reported in recent publications. Nevertheless, our findings are elucidated by the differences in participant characteristics between the two publication periods. Participants in publications prior to 2010 were older and included more women who were shown to have a higher MS prevalence than men in this review.

Despite an unbalanced representation of studies worldwide, the prevalence of MS was essentially similar within and across the major regions including by continent and intra-country site, regardless of the definition criteria used. The absence of studies conducted specifically in rural settings with a likely lower MS prevalence than in urban centres, particularly in developing regions, may account for this finding. Alternatively, it may perhaps reflect the ubiquitous worldwide influence of globalisation and highlight the likelihood of similar influences on the development of MS in the HIV-infected population globally. Thus, broad-based general strategies may perhaps be devised to address the MS burden in all HIV-infected populations.

Strengths and limitations {#sec030}
-------------------------

### Strengths {#sec031}

We searched multiple databases extensively, applying reproducible criteria to capture the most number of studies on MS prevalence worldwide. This allowed us to provide a comprehensive global perspective on the emerging burden of adverse cardio-metabolic profiles in the HIV-infected population. Furthermore, we used robust approaches to pool studies while minimising the effects of extreme studies. We also used a detailed approach to investigate the potential sources of heterogeneity. Our post-hoc power estimation revealed that over two-thirds of the included studies were adequately powered to provide precise estimates of the MS prevalence in the overall sample. This has likely translated into stable and robust pooled estimates by combining those primary studies.

### Limitations {#sec032}

Our findings may not be generalizable to all HIV-infected individuals because most of the studies were conducted in non-randomly selected populations. The wide range in MS prevalence, because of the different criteria used across studies, although expected, made estimations of the actual burden difficult. Nevertheless, apart from differences in the criteria themselves that contributed to this wide range, other factors were also likely responsible. For example, MS prevalence would be expected to differ across time, particularly in the HIV-infected as access to care expanded, the uptake of ART increased and the effectiveness of therapy improved with the introduction of HAART. In some included studies, participants were selected with consideration to histories of existing CVD risk factors, which in turn can result in MS prevalence rates different from those in a broader population of HIV-infected individuals. This could possibly contribute to some of the heterogeneities observed across studies.

The infrequent reporting of the HIV specific markers of CD4 count and viral load precluded in-depth analyses of their effects on MS. Similarly, data were missing on key study characteristics which could be used in advanced analyses via meta-regressions. Furthermore, the inconsistent number of studies across subgroups precluded meta-regression analyses to investigate the possible contribution of each factor to MS prevalence. However, such comparisons would possibly have been biased by differences in study design and objectives, data collection techniques, laboratory facilities and participant characteristics, and could not have been fully accounted for in our meta-analyses. Especially difficult to control for would be HIV related characteristics such as differences in disease stage, fat distribution including lipodystrophy, obesity and co-existent infections such as hepatitis C and hepatitis B \[[@pone.0150970.ref059]\].

Conclusion and Implications {#sec033}
===========================

The MS prevalence in HIV-infected individuals worldwide appears to be similar to that found in the general population, suggesting similarities in the drivers of the syndrome, independent of HIV status. Indeed, despite suggestions of significant signals, the inconsistent association of HIV specific features including treatments with MS prevalence suggest that their contribution, if any, is of a lesser magnitude. Comparable with general populations, traditional risk factors are likely the major contributors to the burden of cardio-metabolic abnormalities and MS in HIV-infected individuals. Therefore, management strategies implemented in the general population for these conditions, will likely reap similar benefits in the HIV-infected. Nevertheless, the major challenge lies in devising and strengthening approaches to maximise cardio-metabolic care while simultaneously ensuring optimal HIV management.
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